IL21 and metastatic melanoma: One patient with melanoma achieved a complete remission (108), in a phase II study evaluating the efficacy and safety profile of IL-21 in patients, with metastatic melanoma, IL-21 was deemed safe and active against metastatic melanoma, with overall response rate being 22.5% and a favorable progression free and OS (109).